Objective To evaluate the efficacy of autologous platelet-rich fibrin (PRF) in the treatment of infertility due to intrauterine adhesion. Methods From October 2018 to October 2019, 40 patients diagnosed as intrauterine adhesion and excluded other infertility factors in Beijing Shijitan Hospital were randomly divided into PRF group and control group, with 20 cases in each group. The intervention lasted for 8 weeks. Patients in both groups underwent transcervical resection of adhesion (TCRA), and PRF was placed in the uterine cavity immediately after TCRA and 4 weeks later in the PRF group. After 8 weeks of TCRA, a second hysteroscopy was performed, and then follow-up was performed. Pregnancy rate, intrauterine adhesions score, menstruation, and endometrial thickness (EMT) were compared between two groups. Results The pregnancy rate of the PRF group was 70.00%, which was significantly higher than 20.00% of the control group (P 0.05). Conclusion The placement of PRF combined with the TCRA can improve the pregnancy rate of infertility due to intrauterine adhesion, reduce intrauterine adhesion scores, and improve clinical symptom.

Objective: To evaluate the efficacy and safety of dienogest (DNG) in the treatment of refractory endometriosis-associated pain (REAP). Methods: In this study, REAP was defined according to the following criteria: (1) the pain duration was ≥12 months and visual analogue scale (VAS)≥60 mm; (2) the previous treatments with over two medicines like oral contraceptives and levonorgestrel-releasing intrauterine system failed to achieve satisfactory relief of pain, with VAS reduction less than 50%; with gonadotropin-releasing hormone agonist or mifepristone, the pain could be controlled temporarily, but it recurred after discontinuation of medicines; (3) the pain could not be relieved by surgery or even repeated surgeries. In the present study, 48 patients with REAP were treated with DNG 2 mg/day orally and the clinical outcomes were retrospectively analyzed. The VAS scores, levels of CA125, estradiol, FSH, LH and changes in the size of endometriotic lesions before and after treatment were compared respectively. The side effects were also analyzed. Results: The average duration of DNG treatment was (20.1±12.8) months. After 3 months of medication, the VAS score was significantly reduced from (77.9±15.8) mm to (20.8±10.7) mm (P<0.01), and CA125 level was significantly reduced from (95±139) kU/L to (38±45) kU/L (P<0.05). The effects were maintained with continuation of DNG treatment. Endometriotic lesions tended to shrink, after 12 months of DNG treatment, the size of ovarian endometriomas was reduced significantly from (3.1±1.0) cm to (1.9±1.2) cm (P<0.05). The mean level of estradiol was maintained at 124.82-221.04 pmol/L and levels of FSH and LH did not change significantly during the treatment. The major side effect was irregular bleeding (75%, 36/48). Conclusions: DNG could effectively relieve REAP and is a well-tolerated therapy. It may supply an alternative option for patients with REAP.

Objective To evaluate the efficacy and safety of direct visualization cold-knife resection via hysteroscopy in the treatment of post-menopausal endometrial polyps.Methods From June 2014 to June 2016,89 patients with post-menopausal endometrial polyps were selected as research objects,and they were divided into observation group(45 cases)and control group(44 cases). Patients in the observation group were treated with direct visualization resection via hysteroscopy,while those in the control group were treated with blind polypectomy following diagnostic hysteroscopy.The operation duration,intraoperative bleeding volume, postoperative complications and recurrence rate of two groups were compared.Results Compared with the control group,the observation group had shorter operation duration,less bleeding volume and shorter postoperative hospital stay with statistically significant differences(t value was -9.18,-1.51 and -1.29,respectively,all P<0.05).There was 1 case of uterus perforation in the control group,but no intraoperative complications occurred in the observation group.Follow -up lasted for 6 to 24 months, during which no relapse in the observation group but 4 in the control group were found.Conclusion Direct visualization resection via hysteroscopy in the treatment of post-menopausal endometrial polyps is effective and safe.

目的:研究佛波酯(TPA)对体外培养的人卵巢癌细胞株SKOV3线粒体DNA(mtDNA)突变的诱导作用.方法:提取细胞DNA,进行mtDNA突变的分析,比较各组细胞之间mtDNA突变率和突变类型的差异.结果:mtDNA的突变热点依次是CoⅡ基因、ND5基因、Crytb基因和ND4基因,在mtDNA突变的测序中发现多个基因突变,突变类型主要为A→T,T→A,G→A,T→C,A→G,C→T,其中C→T为突变热点.结论:Cytb基因的突变可能会对线粒体的氧化过程产生显著的影响.人卵巢癌细胞株SKOV3株mtDNA编码区的C0Ⅱ、Cytb、ND4、ND5基因是一个具有高度多态性和突变性的区域,它与卵巢癌的发生、发展有重要关系.

目的 探讨佛波脂(TPA)诱导分化剂对人卵巢癌细胞株skov3细胞形态的影响.方法 采用四甲基偶氮唑蓝(MTT)快速比色法分析TPA不同浓度及不同时间对人卵巢癌细胞株skov3生长的作用;光镜与透射电镜观察skov3细胞增殖及形态和超微结构的变化.结果 经过诱导分化剂作用后,细胞增殖受到抑制,细胞体积变小,呈现扁平铺展状态,细胞核质比例变小,核仁数量减少.细胞表面微绒毛减少,细胞边缘丝状伪足减少,片状伪足增多,核形态较规则,核内异染色质减少,常染色质增多,细胞质中的细胞器数量增多,结构趋于正常.结论 TPA能够一定程度改变skov3细胞恶性形态结构特征,对skov3细胞具有一定的诱导分化作用.

Objective:To explore the induced effects of 12-tetradecanoyl-phorbol-13-acetate (TPA) on the mtDNA mutation in the ovary cancer cell SKOV3.Methods:DNA was extracted from the SKOV3 cells,then mtDNA mutation was analyzed.The mtDNA mutation rate and type were compared in different groups.Results:The mutational hot spots of mtDNA were Co Ⅱ gene,ND5 gene,Cytb gene and ND4 gene in turn.There were multiple genetic mutations by mtDNA sequencing.The main mutation types were A→T ,T→A,G→A,T→C,A→G,C→T.The C→T mutation was the hot point of mtDNA mutation.Conclusions:Cytb gene mutation might have a significant influence on the oxidative phosphorylation of mitochondria.The mtDNA gene of CoⅡ,Cytb,ND4,ND5 are the highly polymorphic and mutable region in ovary cancer cell SKOV3 that there may be some relations with ovary carcinogenesis and development.

Objective:To study the effects of Curcumin(CCM)、12-tetradecanoyl-phorbol-13-acetate(TPA) on the cell proliferation,morphology and cell cycle of human ovarian cell line SKOV3,to explore the inhibition mechanism of the human ovarian cancer cell line SKOV3.Methods:Growth inhibition rates of SKOV3 cells were measured by MTT method.Morphological changes of cells were observed under fluorescent invert microscope and electromicroscope.Cell cycle was checked by flow cytometery(FCM).Results:CCM can inhibit cell proliferation of SKOV3 in a dose and time dependent manner,growth were hindered at stage G1/S.Partial cells presented the characteristic morphological changes of apoptosis.TPA can inhibit cell proliferation of SKOV3 cell in a does and time dependent manner.Growth were arrested at stage G1→S.Conclusions:CCM and TPA can significantly inhibit the growth of SKOV3 in vitro by inhibiting the cell proliferation and arrest the cell cycle.

Objective To explore the effects of CCM,TPA on mtDNA mutation in skov3 of ovary cancer cell line.Methods High molecular weight genomic DNA isolation was performed.DNA sequencing was done to examine mtDNA mutation after PCR procedure.Results The mtDNA gene mutation in skov3 of ovary cancer cell line was the highly polymorphic and mutable region.The hot points of mtDNA mutation were located in the CoⅡ,ND5,Cytb and ND4 gene successively.By DNA sequencing,mtDNA mutation was concentrated on the points of A→T,T→A,G→A,T→C,A→G,C→T.The C→T mutation was the hottest.Conclusion The mtDNA genes(CoⅡ,Cytb,ND4,ND5) are mutability and polymorphism,which have some relations with ovary carcinogenesis.

[Objective] This study was designed to explore the effects of TPA on the proliferation,morphology,cell cycle distribution and ultrastructure of human ovary cell line SKOV3.[Methods] Grouth inhibition rates of SKOV3 cells were measured with MTT method.Cell cycle distribution and apoptosis was determined by Flow-cytometry.Morphological changes and ultramicrostructure of cells were observed with inverted phase contrast microscope and transmission electron microscope.[Results] TPA could inhibited cell proliferation of human ovary cancer SKOV3 cells in a does-and time-dependent manner.[Conclusions]TPA can inhibite cell proliferation of human ovary cancer skov3 cells and significantly inhibit the growth of ovary cancer cells.